Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: An overview

Current Medicinal Chemistry

Volumn 16, Issue 12, 2009, Pages 1499-1511

  Riou, Laurent M ^a,b   Broisat, A ^a,b   Dimastromatteo, J ^a,b,c   Pons, G ^a,b   Fagret, G ^a,b   Ghezzi, C ^a,b  

^a French Clinical Research Infrastructure Network   (France)

^b UNIV GRENOBLE ALPES   (France)

^c ERAS Labo   (France)

Author keywords

Atherosclerosis; Nuclear molecular imaging; Vulnerable coronary plaque

Indexed keywords

8 QUINOLINOL INDIUM IN 111; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE TC 99M; CHEMOKINE RECEPTOR CCR2; CHOLINE F 18; ENDOTHELIN RECEPTOR; FLUORODEOXYGLUCOSE F 18; INDIUM 111; IODINE 123; IODINE 125; LIPOCORTIN 5; LIPOCORTIN 5 TC 99M; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN I 123; LOW DENSITY LIPOPROTEIN I 125; LOW DENSITY LIPOPROTEIN IN 111; LOW DENSITY LIPOPROTEIN TC 99M; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDA2; MONOCLONAL ANTIBODY MDA2 I 125; MONOCLONAL ANTIBODY MDA2 TC 99M; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1 MONOCLONAL ANTIBODY TC 99M; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DATA ANALYSIS; EARLY DIAGNOSIS; EXPERIMENTAL STUDY; HUMAN; IN VIVO STUDY; INFLAMMATION; ISOTOPE LABELING; MACROPHAGE; METHODOLOGY; MOLECULAR IMAGING; MORTALITY; NON INVASIVE MEASUREMENT; NONHUMAN; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VULNERABLE POPULATION;

EID: 65649109354     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787909596     Document Type: Review

References (124)

1. AHA. Heart disease and stroke statistics - 2006 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation, 2008, 117, e25-e146.
2. Fuster, V.; Moreno, P.R.; Fayad, Z.A.; Corti, R.; Badimon, J.J. AtEerothrombosis and high-risk plaque: Part I: evolving concepts. J. Am. Coll. Cardiol., 2005, 46, 937-54.
3. Naghavi, M.; Libby, P.; Falk, E.; Casscells, S.W.; Litovsky, S.; Rumberger, J.; Badimon, J.J.; Stefanadis, C.; Moreno, P.; Pasterkamp, G.; Fayad, Z.; Stone, P.H.; Waxman, S.; Raggi, P.; Madjid, M.; Zarrabi, A.; Burke, A.; Yuan, C.; Fitzgerald, P.J.; Siscovick, D.S.; de Korte, C.L.; Aikawa, M.; Juhani Airaksinen, K.E.; Assmann, G.; Becker, C.R.; Chesebro, J.H.; Farb, A.; Galis, Z.S.; Jackson, C.; Jang, I.K.; Koenig, W.; Lodder, R.A.; March, K.; Demirovic, J.; Navab, M.; Priori, S.G.; Rekhter, M.D.; Bahr, R.; Grundy, S.M.; Mehran, R.; Colombo, A.; Boerwinkle, E.; Ballantyne, C.; Insull, W. Jr.; Schwartz, R.S.; Vogel, R.; Serruys, P.W.; Hansson, G.K.; Faxon, D.P.; Kaul, S.; Drexler, H.; Greenland, P.; Muller, J.E.; Virmani, R.; Ridker, P.M.; Zipes, D.P.; Shah, P.K.; Willerson, J.T. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation., 2003(a), 108, 1664-72.
4. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-26.
5. Fuster, V.; Fayad, Z.A.; Badimon, J.J. Acute coronary syndromes: biology. Lancet., 1999, 353 Suppl 2, SII5-9.
6. Malek, A.M.; Alper, S.L.; Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA, 1999, 282, 2035-42.
7. Glagov, S.; Weisenberg, E.; Zarins, C.K.; Stankunavicius, R.; Kolettis, G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med., 1987, 316, 1371-5.
8. De Franco, A.C.; Nissen, S.E. Coronary intravascular ultrasound: implications for understanding the development and potential regression of atherosclerosis. Am. J. Cardiol., 2001, 88, 7M-20M.
9. Naghavi, M.; Libby, P.; Falk, E.; Casscells, S.W.; Litovsky, S.; Rumberger, J.; Badimon, J.J.; Stefanadis, C.; Moreno, P.; Pasterkamp, G.; Fayad, Z.; Stone, P.H.; Waxman, S.; Raggi, P.; Madjid, M.; Zarrabi, A.; Burke, A.; Yuan, C.; Fitzgerald, P.J.; Siscovick, D.S.; de Korte, C.L.; Aikawa, M.; Airaksinen K.E.; Assmann, G.; Becker, C.R.; Chesebro, J.H.; Farb, A.; Galis, Z.S.; Jackson, C.; Jang, I.K.; Koenig, W.; Lodder, R.A.; March, K.; Demirovic, J.; Navab, M.; Priori, S.G.; Rekhter, M.D.; Bahr, R.; Grundy, S.M.; Mehran, R.; Colombo, A.; Boerwinkle, E.; Ballantyne, C.; Insull, W. Jr.; Schwartz, R.S.; Vogel, R.; Serruys, P.W.; Hansson, G.K.; Faxon, D.P.; Kaul, S.; Drexler, H.; Greenland, P.; Muller, J.E.; Virmani, R.; Ridker, P.M.; Zipes, D.P.; Shah, P.K.; Willerson, J.T. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation., 2003(b), 108, 1772-8.
10. Schaar J.A.; Mastik F.; Regar E.; den Uil C.A.; Gijsen F.J.; Wentzel J.J.; Serruys P.W.; van der Stehen A.F. Current diagnostic modalities for vulnerable plaque detection. Curr. Pharm. Des. 2007, 13, 995-1001.
11. Naghavi, M.; Falk, E.; Hecht, H.S.; Jamieson, M.J.; Kaul, S.; Berman, D.; Fayad, Z.; Budoff, M.J.; Rumberger, J.; Naqvi, T.Z.; Shaw, L.J.; Faergeman, O.; Cohn, J.; Bahr, R.; Koenig, W.; Demirovic, J.; Arking, D.; Herrera, V.L.; Badimon, J.; Goldstein, J.A.; Rudy, Y.; Airaksinen, J.; Schwartz, R.S.; Riley, W.A.; Mendes, R.A.; Douglas, P.; Shah, P.K. From vulnerable plaque to vulnerable patient: Part III: Executive summary of the screening for heart attack prevention and education (SHAPE) task force report. Am. J. Cardiol., 2006, 98, 2H-15H.
12. Davies, J.R.; Rudd, J.H.; Weissberg, P.L.; Narula, J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J. Am. Coll. Cardiol., 2006, 47, C57-68.
13. Del Guerra, A.; Belcari, N. State-of-the-art of SPECT, PET, and CT for small animal imaging. Nucl. Instrum. Methods Phys. Res. A., 2007, 583, 119-124.
14. Franc, B.L.; Acton, P.D.; Mari, C.; Hasegawa, B.H. Small animal SPECT and SPECT/CT: Important tools for preclinical investigation. J. Nucl. Med., 2008, 49, 1651-63.
15. Stary, H.C.; Chandler, A.B.; Glagov, S.; Guyton, J.R.; Insull, W. Jr.; Rosenfeld, M.E.; Schaffer, S.A.; Schwartz, C.J.; Wagner, W.D.; Wissler, R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1994, 89, 2462-78.
16. Stary, H.C.; Chandler, A.B.; Dinsmore, R.E.; Fuster, V.; Glagov, S.; Insul,l W. Jr.; Rosenfeld, M.E.; Schwartz, C.J.; Wagner, W.D.; Wissler, R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995, 92, 1355-74.
17. Stary, H. Atlas of atherosclerosis - progression and regression. Parthenon Publishing: New York, 1999.
18. Virmani, R.; Kolodgie, F.D.; Burke, A.P.; Farb, A.; Schwartz, S.M. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1262-75.
19. Chatzizisis, Y.S.; Coskun, A.U.; Jonas, M.; Edelman, E.R.; Feldman, C.L.; Stone, P.H. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: Molecular, cellular, and vascular behavior. J. Am. Coll. Cardiol., 2007, 49, 2379-93.
20. Harrison, D.G.; Widder, J.; Grumbach, I.; Chen, W.; Weber, M.; Searles, C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J. Intern. Med., 2006, 259, 351-63.
21. Collins, T.; Cybulsky, M.I. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 2001, 107, 255-64.
22. Kinlay, S.; Libby, P.; Ganz, P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol., 2001, 12, 383-9.
23. Ley, K.; Huo, Y. VCAM-1 is critical in atherosclerosis. J. Clin. Invest., 2001, 107, 1209-10.
24. Steinberg, D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat. Med., 2002, 8, 1211-7.
25. Chitu, V.; Stanley, ER. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol., 2006, 18, 39-48.
26. Dunn, S.; Vohra, R.S.; Murphy, J.E.; Homer-Vanniasinkam, S.; Walker, J.H.; Ponnambalam, S. The lectin-like oxidized low-density-lipoprotein receptor: A pro-inflammatory factor in vascular disease. Biochem. J., 2008, 409, 349-55.
27. Pasterkamp, G.; Van Keulen, J.K.; De Kleijn, D.P. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur. J. Clin. Invest., 2004, 34, 328-34.
28. Schoneveld, A.H.; Hoefer, I.; Sluijter, J.P.; Laman, J.D.; de Kleijn, D.P.; Pasterkamp, G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis., 2008, 197, 95-104.
29. Glass, C.K.; Witztum, J.L. Atherosclerosis. the road ahead. Cell., 2001, 104, 503-16.
30. Mach, F.; Schönbeck, U.; Bonnefoy, J.Y.; Pober, J.S.; Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation, 1997, 96, 396-9.
31. Lutgens, E.; Lievens, D.; Beckers, L.; Donners, M.; Daemen, M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc. Med., 2007, 17, 118-23.
32. Galis, Z.S. Vulnerable plaque: The devil is in the details. Circulation, 2004, 110, 244-6.
33. Newby, A.C. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr. Opin. Lipidol., 2006, 17, 556-61.
34. Steffel, J.; Lüscher, T.F.; Tanner, F.C. Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation, 2006, 113, 722-31.
35. Tedgui, A.; Mallat, Z. Apoptosis as a determinant of atherothrombosis. Thromb. Haemost., 2001, 86, 420-6.
36. Newby, A.C.; Zaltsman, A.B. Fibrous cap formation or destructionthe critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res., 1999, 41, 345-60.
37. Doran, A.C.; Meller, N.; McNamara, C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 812-9.
38. O'Brien, K.D.; McDonald, T.O.; Chait, A.; Allen, M.D.; Alpers, C.E. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation, 1996, 93, 672-82.
39. Moreno, P.R.; Purushothaman, K.R.; Fuster, V.; Echeverri, D.; Truszczynska, H.; Sharma, SK.; Badimon, J.J.; O'Connor, W.N. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation, 2004, 110, 2032-8.
40. Doyle, B.; Caplice, N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J. Am. Coll. Cardiol., 2007, 49, 2073-80.
41. Burke, A.P.; Farb, A.; Malcom, GT.; Liang, Y.H.; Smialek, J.; Virmani, R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med., 1997, 336, 1276-82.
42. Lees, R.S.; Lees, A.M.; Strauss, H.W. External imaging of human atherosclerosis. J. Nucl. Med., 1983, 24, 154-156.
43. Lees, R.S.; Garabedian, H;D.; Lees, A.M.; Schumacher, D.J.; Miller, A.; Isaacsohn, J.L.; Derksen, A.; Strauss, H.W. Technetium- 99m low density lipoproteins: Preparation and biodistribution. J. Nucl. Med., 1985, 26, 1056-62.
44. Vallabhajosula, S.; Paidi, M.; Badimon, J.J.; Le, N.A.; Goldsmith, S.J.; Fuster, V.; Ginsberg, H.N. Radiotracers for low density lipoprotein biodistribution studies in vivo: Technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. J. Nucl. Med., 1988, 29, 1237-45.
45. Lees, A.M.; Lees, R.S.; Schoen, F.J.; Isaacsohn, J.L.; Fischman, A.J.; McKusick, K.A.; Strauss, H.W. Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins. Arteriosclerosis., 1988, 8, 461-470.
46. Rosen, J.M.; Butler, S.P.; Meinken, G.E.; Wang, T.S.; Ramakrishnan, R.; Sristava, S.C.; Alderson, P.O.; Ginsberg, H.N. Indium- 111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J. Nucl. Med., 1990, 31, 343-350.
47. Hay, R.V.; Fleming, R;M.; Ryan, J.W.; Williams, K.A.; Stark, V.J.; Lathrop, K.A.; Harper, PV. Nuclear imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. J. Nucl. Med., 1991, 32, 1239-1245.
48. Virgolini, I.; Angelberger, P.; O'Grady, J.; Sinzinger, H. Low density lipoprotein labelling characterizes experimentally induced atherosclerotic lesions in rabbits in vivo as to presence of foam cells and endothelial coverage. Eur. J. Nucl. Med., 1991, 18, 944-947.
49. Pirich, C.; Sinzinger, H. Evidence for lipid regression in humans in vivo performed by 123Iodine-low-density lipoprotein scintiscanning. Ann. N Y Acad. Sci., 1995, 748, 613-21.
50. Iuliano, L.; Signore, A.; Vallabajosula, S.; Colavita, A.R.; Camastra, C.; Ronga, G.; Alessandri, C.; Sbarigia, E.; Fiorani, P.; Violi, F. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man. Atherosclerosis., 1996, 126, 131-41.
51. Hardoff, R.; Braegelmann, F.; Zanzonico, P.; Herrold, E.M.; Lees, R.S.; Lees, A.M.; Dean, R.T.; Lister-James, J.; Borer, J.S. External imaging of atherosclerosis in rabbits using an 123I-labeled synthetic peptide fragment. J. Clin. Pharmacol., 1993, 33, 1039-47.
52. Hardoff, R.; Zanzonico, P.; Braegelmann, F.; Herrold, E.M.; Lees, R.S.; Lees, A.M.; Dean, R;T.; Lister-James, J.; Borer, J.S. Localization of (99m)Tc-labeled apoB synthetic peptide in arterial lesions of an experimental model of spontaneous atherosclerosis. Am. J. Ther., 1995, 2, 88-99.
53. Tsimikas, S.; Palinski, W.; Halpern, S.E.; Yeung, D.W.; Curtiss, L.K.; Witztum, J.L. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J. Nucl. Cardiol., 1999, 6, 41-53.
54. Torzewski, M.; Shaw, P.X.; Han, K.R.; Shortal, B.; Lackner, K.J.; Witztum, J.L.; Palinski, W.; Tsimikas, S. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2307-12.
55. Tsimikas, S.; Shortal, B.P.; Witztum, J.L.; Palinski, W. In vivo uptake of radiolabeled MDA2.; an oxidation-specific monoclonal antibody.; provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 689-97.
56. Shaw, P.X.; Hörkkö, S.; Tsimikas, S.; Chang, M.K.; Palinski, W.; Silverman, G.J.; Chen, P.P.; Witztum, J.L. Human-derived antioxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1333-9.
57. Tsimikas, S.Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am. J. Cardiol., 2002, 90, 22L-27L.
58. Langer, H.F.; Haubner, R.; Pichler, B.J.; Gawaz, M. Radionuclide imaging: A molecular key to the atherosclerotic plaque. J. Am. Coll. Cardiol., 2008, 52, 1-12.
59. Vohra, R.S.; Murphy, J.E.; Walker, J.H.; Ponnambalam, S.; Homer-Vanniasinkam, S. Atherosclerosis and the Lectin-like OXidized low-density lipoprotein scavenger receptor. Trends Cardiovasc. Med., 2006, 16, 60-4.
60. Kataoka, H.; Kume, N.; Miyamoto, S.; Minami, M.; Moriwaki, H.; Murase, T.; Sawamura, T.; Masaki, T.; Hashimoto, N.; Kita, T. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation., 1999, 99, 3110-7.
61. Ishino, S.; Mukai, T.; Kuge, Y.; Kume, N.; Ogawa, M.; Takai, N.; Kamihashi, J.; Shiomi, M.; Minami, M.; Kita, T.; Saji, H. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: Potential agent for imaging of vulnerable plaque. J. Nucl. Med., 2008, 49, 1677-85.
62. Ogawa, M.; Ishino, S.; Mukai, T.; Asano, D.; Teramoto, N.; Watabe, H.; Kudomi, N.; Shiomi, M.; Magata, Y.; Iida, H.; Saji, H. (18)F-FDG accumulation in atherosclerotic plaques: Immunohistochemical and PET imaging study. J. Nucl. Med., 2004, 45, 1245-50.
63. Ishino, S.; Kuge, Y.; Takai, N.; Tamaki, N.; Strauss, H.W.; Blankenberg, F.G.; Shiomi, M.; Saji, H. 99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: Imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 889-99.
64. Ohtsuki, K.; Hayase, M.; Akashi, K.; Kopiwoda, S.; Strauss H.W. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study. Circulation, 2001, 104, 203-8.
65. Hartung, D.; Petrov, A.; Haider, N.; Fujimoto, S.; Blankenberg, F.; Fujimoto, A.; Virmani, R.; Kolodgie, F.D.; Strauss, HW.; Narula, J. Radiolabeled Monocyte Chemotactic Protein 1 for the detection of inflammation in experimental atherosclerosis. J. Nucl. Med., 2007, 48, 1816-21.
66. Rudd, J.H.; Warburton, E.A.; Fryer, T.D.; Jones, H.A.; Clark, J.C.; Antoun, N.; Johnström, P.; Davenport, A.P.; Kirkpatrick, P.J.; Arch, B.N.; Pickard, J.D.; Weissberg P.L. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation, 2002, 105, 2708-11.
67. Rudd, J.H.; Myers, K.S.; Bansilal, S.; Machac, J.; Rafique, A.; Farkouh, M.; Fuster, V.; Fayad, ZA. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol., 2007, 50, 892-6.
68. Tawakol, A.; Migrino, R.Q.; Hoffmann, U.; Abbara, S.; Houser, S.; Gewirtz, H.; Muller, J.E.; Brady, T.J.; Fischman, A.J. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J. Nucl. Cardiol., 2005, 12, 294-301.
69. Tawakol, A.; Migrino, R.Q.; Bashian, G.G.; Bedri, S.; Vermylen, D.; Cury, R.C.; Yates, D.; LaMuraglia, G.M.; Furie, K.; Houser, S.; Gewirtz, H.; Muller, J.E.; Brady, T.J.; Fischman, A.J. In vivo 18Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol., 2006, 48, 1818-24.
70. Calcagno, C.; Cornily, J.C.; Hyafil, F.; Rudd, J.H.; Briley-Saebo, K.C.; Mani, V.; Goldschlager, G.; Machac, J.; Fuster, V.; Fayad, Z. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1311-7.
71. Tahara, H.; Kai, H.; Nakaura, H.; Mizoguchi, M.; Ishibashi, M.; Kaida, H.; Baba, K.; Hayabuchi, N.; Imaizumi, T. The prevalence of inflammation in carotid atherosclerosis: Analysis with fluorodeoxyglucose- positron emission tomography. Eur. Heart J., 2007(a), 28, 2243-48.
72. Tahara, H.; Kai, H.; Yamagishi, S.; Mizoguchi, M.; Nakaura, H.; Ishibashi, M.; Kaida, H.; Baba, K.; Hayabuchi, N.; Imaizumi, T. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J. Am. Coll. Cardiol., 2007(b), 49, 1533-9.
73. Tahara, N.; Kai, H.; Ishibashi, M.; Nakaura, H.; Kaida, H.; Baba, K.; Hayabuchi, N.; Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol., 2006, 48, 1825-31.
74. Ogawa, M.; Magata, Y.; Kato, T.; Hatano, K.; Ishino, S.; Mukai, T.; Shiomi, M.; Ito, K.; Saji, H. Application of 18F-FDG-PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J. Nucl. Med., 2006, 47, 1845-50.
75. Laurberg, J.M.; Olsen, A.K.; Hansen, S.B.; Bottcher, M.; Morrison, M.; Ricketts, S.A.; Falk, E. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: No FDG accumulation. Atherosclerosis, 2007, 192, 275-82.
76. Rudd, J.H.; Fayad, Z.A.; Machac, J.; Weissberg, P.L.; Davies, J.R.; Warburton, E.A.; Tawakol, A.A.; Strauss, H.W.; Fuster, V. Response to 'Laurberg, J.M.; Olsen, A.K.; Hansen, S.B.; et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: No FDG accumulation' i Atherosclerosis 2006]. Atherosclerosis, 2007, 192, 453-4; author reply 451-2.
77. Lederman, R.J.; Raylman, R.R.; Fisher, S.J.; Kison, P.V.; San, H.; Nabel, E.G.; Wahl, R.L. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl. Med. Commun., 2001, 22, 747-53.
78. Mukai, T.; Nohara, R.; Ogawa, M.; Ishino, S.; Kambara, N.; Kataoka, N.; Kanoi, T.; Saito, K.; Motomura, H.; Konishi, J.; Saji, H. A catheter-based radiation detector for endovascular detection of atheromatous plaques. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1299-303.
79. Hosokawa, R.; Kambara, N.; Ohba, M.; Mukai, T.; Ogawa, M.; Motomura, H.; Kume, N.; Saji, H.; Kita, T.; Nohara, R. A catheterbased intravascular radiation detector of vulnerable plaques. J. Nucl. Med., 2006, 47, 863-7.
80. Strauss, H.W.; Mari, C.; Patt, B.E.; Ghazarossian, V. Intravascular radiation detectors for the detection of vulnerable atheroma. J. Am. Coll. Cardiol., 2006, 47, C97-C100.
81. Shikhaliev, P.M.; Xu, T.; Ducote, J.L.; Easwaramoorthy, B.; Mukherjee, J.; Molloi, S. Positron autoradiography for intravascular imaging: feasbility evaluation. Phys. Med. Biol., 2006, 51, 963-79.
82. Schmid, D.T.; John, H.; Zweifel, R.; Cservenyak, T.; Westera, G.; Goerres, G.W.; von Schulthess, G.K.; Hany, T.F. Fluorocholine PET/CT in patients with prostate cancer: Initial experience. Radiology., 2005, 235, 623-8.
83. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine and 1-Ooctadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDPcholine pathway of phosphatidylcholine synthesis at the CTP: phosphocholine cytidylyltransferase step. J. Biol. Chem., 1995, 270, 7757-64.
84. Wyss, M.T.; Weber, B.; Hoenr, M.; Spath, N.; Ametamey, S.M.; Westera, G.; Bode, B.; Kaim, A.H.; Buck, A. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 312-6.
85. Spaeth, N.; Wyss, M.T.; Weber, B.; Scheidegger, S.; Lutz, A.; Verwey, J.; Radovanovic, I.; Pahnke, J.; Wild, D.; Westera, G.; Weishaupt, D.; Hermann, D.M.; Kaser-Hotz, B.; Aguzzi A.; Buck A. Uptake of 18F-fluorocholine.; 18F-fluoroethyl-L-tyrosine.; and 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumor recurrence. J. Nucl. Med., 2004, 45, 1931-8.
86. Matter, C.M.; Wyss, M.T.; Meier, P.; Späth, N.; von Lukowicz, T.; Lohmann, C.; Weber, B.; Ramirez de Molina, A.; Lacal J.C.; Ametamey, S.M.; von Schulthess, G.K.; Lüscher T.F.; Kaufmann, P.A.; Buck, A. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 584-9.
87. Kircher, M.F.; Grimm, J.; Swirski, F.K.; Libby, P.; Gerszten, R.E.; Allport, J.R.; Weissleder R. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation, 2008, 22, 388-95.
88. Nahrendorf, M.; Zhang, H.; Hembrador, S.; Panizzi, P.; Sosnovik, D.E.; Aikawa, E.; Libby, P.; Swirski, F.K.; Weissleder, R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation, 2008, 117, 379-87.
89. Hamilton, A.J.; Huang, S.L.; Warnick, D.; Rabbat, M.; Kane, B.; Nagaraj, A.; Klegerman, M.; McPherson, D.D. Intravascular ultrasound molecular imaging of atheroma components in vivo. J. Am. Coll. Cardiol., 2004, 43, 453-60.
90. Kelly, K.A.; Allport, J.R.; Tsourkas, A.; Shinde-Patil, V.R.; Jospehson, L.; Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res., 2005, 96, 327-36.
91. Nahrendorf, M.; Jaffer, F.A.; Kelly, K.A.; Sosnovik, D.E.; Aikawa, E.; Libby, P.; Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 2006, 114, 1504-11.
92. Kaufmann, B.A.; Sanders, J.M.; Davis, C.; Xie, A.; Aldred, P.; Sarembock, I.J.; Lindner, J.R. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation, 2007, 116, 276-84.
93. Broisat, A.; Riou, L.M.; Ardisson, V.; Boturyn, D.; Dumy, P.; Fagret, D.; Ghezzi, C. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 830-40.
94. Ling, X.; Tamaki, T.; Xiao, Y.; Kamangar, S.; Clayberger, C.; Lewis, D.B.; Krensky, A.M. An immunosuppressive and anti-inflammatory HLA class I-derived peptide binds vascular cell adhesion molecule-1. Transplantation, 2000, 27, 662-7.
95. Dimastromatteo, J.; Ahmadi, M.; Broisat, A.; Riou, L.M.; Boturyn, D.; Dumy, P.; Fagret, D.; Ghezzi, C. In vivo Molecular Imaging of Vascular Cell Adhesion Molecule-1 Expression in Atherosclerotic Plaques [Oral communication]. Annual Congress of the European Association of Nuclear Medicine, October 11th - 15th, 2008, Munich, Germany.
96. Kopka, K.; Breyholz, H.J.; Wagner, S.; Law, M.P.; Riemann, B.; Schröer, S.; Trub, M.; Guilbert, B.; Levkau, B.; Schober, O.; Schäfers, M. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl. Med. Biol., 2004, 31, 257-67.
97. Schäfers, M.; Riemann, B.; Kopka, K.; Breyholz, H.J.; Wagner, S.; Schäfers, K.P.; Law, M.P.; Schober, O.; Levkau, B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation., 2004, 109, 2554-9.
98. Breyholz, H.J.; Wagner, S.; Levkau, B.; Schober, O.; Schäfers, M.; Kopka, K. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q. J. Nucl. Med. Mol. Imaging., 2007, 51, 24-32.
99. Wagner, S.; Breyholz, H.J.; Law, M.P.; Faust, A.; Höltke, C.; Schröer, S.; Haufe, G.; Levkau, B.; Schober, O.; Schäfers, M.; Kopka, K. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)- (4-methoxyphenyl)sulfonyl] (benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J. Med. Chem., 2007, 50, 5752-5764.
100. Breyholz, H.J.; Schäfers, M.; Wagner, S.; Hôltke, C.; Faust, A.; Rabeneck, H.; Levkau, B.; Schober, O.; Kopka, K. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J. Med. Chem., 2005, 48, 3400-09.
101. Kolodgie, F.D.; Petrov, A.; Virmani, R.; Narula, N.; Verjans, J.W.; Weber, D.K.; Hartung, D.; Steinmetz, N.; Vanderheyden, J.L.; Vannan, M.A.; Gold, H.K.; Reutelingsperger, C.P.; Hofstra, L.; Narula, J. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: A technique with potential for noninvasive imaging of vulnerable plaque Circulation, 2003, 108, 3134-9.
102. Johnson, L.L.; Schofield, L.; Donahay, T.; Narula, N.; Narula J. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J. Nucl. Med., 2005, 46, 1186-93.
103. Isobe, S.; Tsimikas, S.; Zhou, J.; Fujimoto, S.; Sarai, M.; Branks, M.J.; Fujimoto, A.; Hofstra, L.; Reutelingsperger, C.P.; Murohara, T.; Virmani, R.; Kolodgie, F.D.; Narula, N.; Petrov, A.; Narula, J. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J. Nucl. Med., 2006, 47, 1497-505.
104. Hartung, D.; Sarai, M.; Petrov, A.; Kolodgie, F.; Narula, N.; Verjans, J.; Virmani, R.; Reutelingsperger, C.; Hofstra, L.; Narula, J. Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J. Nucl. Med., 2005, 46, 2051-6.
105. Sarai, M.; Hartung, D.; Petrov, A.; Zhou, J.; Narula, N.; Hofstra, L.; Kolodgie, F.; Isobe, S.; Fujimoto, S.; Vanderheyden, J.L.; Virmani, R.; Reutelingsperger, C.; Wong, N.D.; Gupta, S.; Narula, J. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. J. Am. Coll. Cardiol., 2007, 50, 2305-12.
106. Zhao, Y.; Kuge, Y.; Zhao, S.; Morita, K.; Inubushi, M.; Strauss, H.W.; Blankenberg, F.G.; Tamaki, N. Comparison of 99mTc-annexin A5 with 18F-FDG for the detection of atherosclerosis in ApoE-/- mice. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1747-1755.
107. Kemerink, G.J.; Liu, X.; Kieffer, D.; Ceyssens, S.; Mortelmans, L.; Verbruggen, A.M.; Steinmetz, N.D.; Vanderheyden, J.L.; Green, A.M.; Verbeke, K. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med., 2003, 44, 947-52.
108. Kietselaer, B.L.; Reutelingsperger, C.P.; Heidendal, G.A.; Daemen, M.J.; Mess, W.H.; Hofstra, L.; Narula, J. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J. Med., 2004, 350, 1472-3.
109. Elmaleh, D.R.; Narula, J.; Babich, J.W.; Petrov, A.; Fischman, A.J.; Khaw, B.A.; Rapaport, E.; Zamecnik, P.C. Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates. Proc. Natl. Acad. Sci. U S A., 1998, 95, 691-5.
110. Bauer, C.; Bauder-Wuest, U.; Mier, W.; Haberkorn, U.; Eisenhut, M. 131I-labeled peptides as caspase substrates for apoptosis imaging. J. Nucl. Med., 2005, 46, 1066-74.
111. Aloya, R.; Shirvan, A.; Grimberg, H.; Reshef, A.; Levin, G.; Kidron, D.; Cohen, A.; Ziv, I. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis, 2006, 11, 2089-101.
112. Faust, A; Wagner, S; Law, M.P.; Hermann, S; Schnöckel, U.; Keul, P.; Schober, O.; Schäfers, M.; Levkau, B.; Kopka, K. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl) -5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q. J. Nucl. Med. Mol. Imaging., 2007, 51, 67-73.
113. Luo, Q.Y.; Wang, F.; Zhang, Z.Y.; Zhang, Y.; Lu, H.K.; Sun, S.H.; Zhu, R.S. Preparation and bioevaluation of (99m)Tc-HYNIC annexin B1 as a novel radioligand for apoptosis imaging. Apoptosis., 2008, 13, 600-8.
114. Dinkelborg, L.M.; Duda, S.H.; Hanke, H.; Tepe, G.; Hilger, C.S.; Semmler, W. Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative. J. Nucl. Med., 1998, 39, 1819-22.
115. Tepe, G.; Duda, S.H.; Meding, J.; Brehme, U.; Ritter, J.; Hanke, H.; Hilger, C.S.; Claussen, C.D.; Dinkelborg, L.M. Tc-99m-labeled endothelin derivative for imaging of experimentally induced atherosclerosis. Atherosclerosis., 2001, 157, 383-92.
116. Meding, J.; Dinkelborg, L.M.; Grieshaber, M.K.; Semmler, W. Targeting of endothelin receptors for molecular imaging of atherosclerosis in rabbits. J. Nucl. Med., 2002, 43, 400-5.
117. Sadeghi, M.M.; Krassilnikova, S.; Zhang, J.; Gharaei, A.A.; Fassaei, H.R.; Esmailzadeh, L.; Kooshkabadi, A.; Edwards, S.; Yalamanchili, P.; Harris, T.D.; Sinusas, A.J.; Zaret, B.L.; Bender, J.R.. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation., 2004, 110, 84-90.
118. Matter, C.M.; Schuler, P.K.; Alessi, P.; Meier, P.; Ricci, R.; Zhang, D.; Halin, C.; Castellani, P.; Zardi, L.; Hofer, C.K.; Montani, M.; Neri, D.; Lüscher, T.F. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ. Res., 2004, 95, 1225-33.
119. von Lukowicz, T.; Silacci, M.; Wyss M.T.; Trachsel, E.; Lohmann, C.; Buck, A.; Lüscher, T.F.; Neri, D.; Matter, C.M. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J. Nucl. Med., 2007, 48, 582-7.
120. Thurberg, BL; Collins, T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr. Opin. Lipidol., 1998, 9, 387-96.
121. De Nigris, F.; Lerman, L.O.; Rodriguez-Porcel, M.; De Montis, M.P.; Lerman, A.; Napoli C. C-myc activation in early coronary lesions in experimental hypercholesterolemia. Biochem. Biophys. Res. Commun., 2001, 281, 945-50.
122. Qin, G.; Zhang, Y.; Cao, W; An, R.; Gao, Z.; Li, G.; Xu, W.; Zhang, K.; Li, S. Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 6-14.
123. Scanlon, K.J.Anti-genes: SiRNA, ribozymes and antisense. Curr. Pharm. Biotechnol., 2004, 5, 415-20.
124. Blankenberg, F.G.; Strauss, H.W. Nuclear medicine applications in molecular imaging: 2007 update. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 99-110.